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Chromosomal microarray testing in adults with
intellectual disability presenting with comorbid
psychiatric disorders
Kate Wolfe*,1, André Strydom1, Deborah Morrogh2, Jennifer Carter2, Peter Cutajar3, Mo Eyeoyibo4,
Angela Hassiotis1, Jane McCarthy5, Raja Mukherjee6, Dimitrios Paschos7, Nagarajan Perumal8, Stephen Read9,
Rohit Shankar10, Saif Sharif11, Suchithra Thirulokachandran12, Johan H Thygesen1, Christine Patch13,
Caroline Ogilvie13, Frances Flinter13, Andrew McQuillin1 and Nick Bass1
Chromosomal copy-number variations (CNVs) are a class of genetic variants highly implicated in the aetiology of
neurodevelopmental disorders, including intellectual disabilities (ID), schizophrenia and autism spectrum disorders (ASD). Yet
the majority of adults with idiopathic ID presenting to psychiatric services have not been tested for CNVs. We undertook genome-
wide chromosomal microarray analysis (CMA) of 202 adults with idiopathic ID recruited from community and in-patient ID
psychiatry services across England. CNV pathogenicity was assessed using standard clinical diagnostic methods and participants
underwent comprehensive medical and psychiatric phenotyping. We found an 11% yield of likely pathogenic CNVs (22/202).
CNVs at recurrent loci, including the 15q11-q13 and 16p11.2-p13.11 regions were most frequently observed. We observed an
increased frequency of 16p11.2 duplications compared with those reported in single-disorder cohorts. CNVs were also identiﬁed
in genes known to effect neurodevelopment, namely NRXN1 and GRIN2B. Furthermore deletions at 2q13, 12q21.2-21.31 and
19q13.32, and duplications at 4p16.3, 13q32.3-33.3 and Xq24-25 were observed. Routine CMA in ID psychiatry could
uncover ~ 11% new genetic diagnoses with potential implications for patient management. We advocate greater consideration of
CMA in the assessment of adults with idiopathic ID presenting to psychiatry services.
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INTRODUCTION
Intellectual disability (ID) is deﬁned as signiﬁcant impairments in
intellectual and adaptive functioning with onset before the age of 18
years. ID is a clinically heterogeneous disorder with a range of genetic
and environmental causes. Genetic causes include aneuploidies, copy-
number variations (CNVs) and single-nucleotide variants in speciﬁc
genes. There are a wide range of environmental causes, notably
perinatal infection and hypoxic injury. For ~ 50% of individuals with
ID the cause is unknown.1 There is an increased prevalence of
psychiatric disorders in adults with ID, for example the point
prevalence of psychosis has been estimated as 10 times higher than
the general population.2 In the United Kingdom adult ID psychiatry
is a specialist ﬁeld. Investigation of the cause of ID/developmental
delay (DD) predominately occurs at onset in childhood and there
is no formalised system of diagnostic review. Genetic testing in
adulthood can be carried out by ID psychiatrists and other treating
clinicians, such as neurologists. Clinical genetics services are organised
regionally in the UK and treating clinicians can make onward referrals
for patients and families. Screening for genetic causes of ID
has advanced from G-banded karyotyping to high-resolution
genome-wide chromosomal microarray analysis (CMA), which is
often the recommended ﬁrst-tier cytogenetic test for DD/ID.3
CMA encompasses array comparative genomic hybridisation
(aCGH) and single-nucleotide polymorphism arrays, which detect
submicroscopic losses or gains of genetic material known as CNVs.
The clinical relevance of CNV events is determined by factors such as
the inheritance pattern, size of the CNV, number of genes deleted or
duplicated, likely functional consequence of gene disruption and
presence of the CNV in healthy control data sets.3 Recurrent CNVs
are found in regions of the genome harbouring simple repetitive DNA
sequences known as low copy repeats. Propensity to recombination
errors in these regions give rise to some of the well-known syndromic
forms of ID, for example the recurrent deletions at the 15q11-q13
region which cause Prader Willi or Angelman’s syndrome. CNVs can
also be classed as pathogenic when there is a disruption of genes
involved in important neurodevelopmental functions, such as
neurotransmission.4
A CNV ‘morbidity map’ has identiﬁed 70 CNV regions signiﬁcantly
associated with DD/ID in 29 085 children; however, comparable data
on adults with ID are limited.4 Study of research cohorts with
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schizophrenia and ASD have also revealed rare recurrent CNVs that
are very strong risk factors for the development of these disorders.5,6
It has now been shown that some CNVs confer risk for multiple
neurodevelopmental disorders. For example duplication at the
16p11.2 locus increases risk for ID and ASD and has been shown to
be associated with a 14-fold increased risk of psychosis.7 Thus
rare recurrent CNVs have broad, and often comorbid, neuro-
developmental phenotypes operating across traditional diagnostic
boundaries.
Historically genetic investigation has not been a routine part of the
assessment of adults with ID presenting to psychiatric services.8
However, the emergence of CNVs as important risk factors for
multiple disorders raises the possibility that individuals with comorbid
neurodevelopmental conditions should be prioritised where CMA
testing is offered. We investigated the presence of undiagnosed likely
pathogenic CNVs in adults with idiopathic ID presenting to commu-
nity and in-patient psychiatric services in England. We discuss the
frequency and type of CNVs identiﬁed; the associated phenotype and
the implications of our ﬁndings.
METHODS
Study design and participant recruitment
Recruitment was undertaken via the Mental Health Research Network
(MHRN) at 32 National Health Service (NHS) trusts and 1 non-NHS provider
across England between August 2012 and March 2014. Consultant Psychiatrists
in Intellectual Disabilities acted as local investigators at each site. Local
investigators identiﬁed eligible participants from their caseloads based upon
the study inclusion criteria, namely that the participants should be aged 18
years or older with idiopathic ID, one or more psychiatric diagnoses and/or
signiﬁcant challenging behaviours. Typically in the UK services use a high
threshold for eligibility of ID services (IQo70 as well as signiﬁcant impairment
of functioning which has been present from childhood). Idiopathic ID was
deﬁned as no clear genetic or environmental cause of ID detailed on the
participant’s medical records. Capacity to consent to the research project was
assessed in accordance with the Mental Capacity Act 2005. Easy read
information sheets and consent forms were utilised with individuals who had
capacity to consent. In the absence of capacity consultees were identiﬁed to give
advice as to the person’s likely wishes regarding participation.
Clinical data including medical and psychiatric history (International
Statistical Classiﬁcation of Diseases and Related Health Problems (ICD-10)
diagnoses), was collected from an informant and/or medical records. General
observations for dysmorphic features were made and measurements of height
and head circumference were collected by the clinician or researcher.
Photographs were taken (where consent was given) for corroboration by the
study team. Detailed psychiatric and behavioural phenotyping was undertaken
using the Mini Psychiatric Assessment Schedule for Adults with Developmental
Disabilities (Mini PAS-ADD) and Behaviour Problems Inventory - Short Form
(BPI-S). The Mini PAS-ADD assesses psychiatric symptoms in seven diagnostic
areas and provides threshold scores for symptoms that are likely to warrant a
diagnosis in conjunction with a clinical assessment.9 The BPI-S provides
frequency scores of behaviours on three domains, self-injurious behaviour,
aggressive/destructive behaviour and stereotyped behaviour.10 Symptoms iden-
tiﬁed from Mini PAS-ADD or BPI-S screening are referred to as subclinical
symptoms in the manuscript.
Genetic analysis and feedback
Participants provided either a blood (24%) or saliva sample (76%) for DNA
extraction. aCGH analysis was undertaken at the North East Thames Regional
Genetics Service Laboratory on the Nimblegen 135K platform. Arrays were
processed and CNVs were reported using clinical diagnostic laboratory
protocols, in keeping with the Association for Clinical Genetic Science (ACGS)
best practice guidelines.11 CNVs referred to in the manuscript as likely
pathogenic include pathogenic causative ﬁndings and pathogenic susceptibility
loci, both of which are thought to affect gene function in view of the
associated phenotype.12 All likely pathogenic CNVs detailed in this manuscript
were validated by qPCR, FISH or QF PCR and have been added to the
Decipher genome browser.13 The other classes of CNV reported were variants
of uncertain clinical signiﬁcance (VOUS) and likely benign CNVs. Classiﬁcation
as VOUS includes: intronic CNVs, CNVs where no genes are present, CNVs
where no entry was present on the Database of Genomic Variants (at the time
of analysis), in addition to those where insufﬁcient information is available to
classify further. Further analysis has not been undertaken and these CNVs may
include technical artefacts. Chromosomal abnormalities were also reported.
Further analysis of relevant literature, and patient and control data sets was
conducted by the research team and collaborators.
Likely pathogenic CNVs were fed back in writing to the participants’ treating
psychiatrist. The cytogenetic report detailing relevant CNVs and associated
publications were provided alongside chromosomal disorder guides from the
support group Unique where available.14 There is a paucity of appropriate and
accessible information for adults with ID receiving diagnoses. The study
team developed easy to read materials to aid feedback for some of the
clinically relevant CNVs. Psychiatrists also had the opportunity to speak
with a member of the research team regarding the result prior to feeding
this back to their patients and family members and/or carers. Referral to
the regional clinical genetics service was recommended for all likely
pathogenic results. There were no adverse outcomes reported from feed-
back of the genetic test results.
Statistical analysis
Statistical analyses were undertaken using IBM SPSS Statistics for Windows,
Version 22.0 (IBM Corp, Armonk, NY, USA). Univariate binary logistic
regression was performed using Mini PAS-ADD thresholds and history of
involuntary in-patient admission, including forensic in-patient section, as
predictor variables. The binary outcome variable was presence or absence of
a likely pathogenic CNV.
RESULTS
A total of 202 adults with idiopathic ID and comorbid psychiatric
disorders/challenging behaviour were recruited to the study (63%
male; mean age 37 years, range 18–78 years; 74% White British). The
yield of likely pathogenic CNVs, including chromosomal abnormal-
ities, was 11% (22/202). A further 62% of participants had a least one
CNV classed as a VOUS (126/202) and 27% (54/202) had likely
benign CNVs only. Details of the VOUS CNVs can be found in the
Supplementary Information. An overview of likely pathogenic CNVs is
presented in Figure 1, with detailed genetic and phenotypic data
presented in Table 1 and Supplementary Table 1. A comparison of
psychiatric diagnoses, subclinical symptoms and section history for
likely pathogenic versus likely benign (including VOUS) CNVs is
provided in Table 2. There were 21 participants on a forensic in-
patient section at the time of recruitment and no other participants
had a forensic section history. In all, 6/21 forensic in-patients carried
likely pathogenic CNVs compared with 16/181 in participants not on a
forensic in-patient section. Thus the proportion of likely pathogenic
CNV carriers in forensic in-patients was higher with an OR of 4.1
(95% CI 1.40–12.04, P= 0.01).
Neurodevelopmental CNVs
Most of the likely pathogenic CNVs were observed in regions of the
genome prone to recurrent CNV. Five of these CNVs were identiﬁed
at the 16p11.2 locus (4 duplications, 1 deletion) and one duplication at
16p13.11. The 16p11.2 region is associated with increased risk for
ASD, schizophrenia and major depressive disorder, in keeping with the
phenotypes observed in this cohort.15 A further ﬁve CNVs were
identiﬁed in the 15q11.2-13.3 region (15q11.2 deletion, Angelman
syndrome type 2, 15q12-13.1 deletion, 15q11.2-13.1 duplication and
15q13.3 deletion) with variable psychiatric phenotypes. The CNVs at
CMA in ID and comorbid psychiatric disorders
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15q11.2, 15q13.3, 16p11.2 and 16p13.11 affect neurosusceptibility loci.
These likely pathogenic CNVs have incomplete penetrance in that they
occur at higher frequencies in disease cohorts, however, are not always
associated with a disease phenotype and can sometimes be observed in
healthy controls.
Another region prone to recurrent CNV is the 17q11.2 locus, which
encompasses the neuroﬁbromatosis type 1 (NF1) tumour suppressor
gene. We identiﬁed a participant with a NF1 microdeletion presenting
with a clinical diagnosis of ASD and challenging behaviours.
This supports previous evidence of ASD being associated with variants
in the NF1 gene.16 We also identiﬁed a deletion at 2q13 in a patient
with a clinical diagnosis of ASD. Of the 29 patients described with this
CNV 4 are reported to have ASD.17 CNVs in this region have also
been shown to be enriched in schizophrenia cohorts,18 the participant
presented with subclinical features of psychosis in addition to anxiety
and behavioural problems. Two CNVs were identiﬁed in genes known
to be important in neurodevelopment, namely GRIN2B and NRXN1.
The GRIN2B gene is located at 12p13.1 and encodes the NR2 subunit
of a N-methyl-D-aspartate glutamate receptor heteromer, which
mediates excitatory neurotransmission and is thought to have an
important role in memory and learning. Variants in the GRIN2B gene
have previously been associated with behavioural problems.19 We
identiﬁed a duplication affecting exon 9 of the GRIN2B gene in a
participant displaying self-injurious and aggressive behaviours. The
NRXN1 gene is located at 2p16.3, it encodes a cell-surface receptor
which is important for neurotransmission. Exonic NRXN1 deletions
have been associated with increased risk for schizophrenia and ASD.20
Our participant has a deletion of exon 1 of the NRXN1 gene, a clinical
diagnosis of personality disorder and subclinical symptoms of
psychosis and stereotyped behaviour.
Five of the likely pathogenic CNVs identiﬁed have little or no
prior association with psychiatric phenotypes in existing literature
and likely represent rare emerging neurodevelopmental CNVs.
First, we identiﬁed a duplication of 4p16.3, a region where deletions
give rise to the better characterised Wolf–Hirschhorn syndrome.
The CNV identiﬁed in our sample partially overlaps with the CNV
reported in a case study of a patient with attention-deﬁcit hyperactivity
disorder (ADHD).21 Our participant had a clinical diagnosis of
ASD and was a forensic in-patient. A duplication at Xq24-25 was
observed in a participant with aggressive and stereotyped behaviours.
Abnormal behaviours, primarily hyperactivity, have previously been
associated with CNVs in this region. The STAG2 gene, which encodes
a component of the cohesion complex and is essential for chromo-
some segregation in dividing cells, has been identiﬁed as the likely
causative gene.22
We identiﬁed a participant with a deletion at 12q21.2-21.31
comprising 17 genes. This region contains the Synaptotagmin-1
(SYT1) gene, which encodes a calcium-binding synaptic vesicle
membrane protein involved in triggering neurotransmitter release at
the synapse. A variant in SYT1, with a dominant negative function,
has recently been associated with profound cognitive impairment.23
Whilst we observe a copy-number loss and different phenotype,
a low haploinsufﬁciency score is suggestive of adverse functional
consequences.24 The participant has a clinical diagnosis of paranoid
schizophrenia, a history of alcohol abuse and was a forensic in-patient.
Another participant has a duplication at 13q32.3-13q33.3 comprising
33 genes. This region contains the D-amino acid oxidase activator
(DAOA) gene, which indirectly affects glutamatergic transmission and
dopamine turnover. We and others have reported DAOA to be
associated with both schizophrenia and bipolar affective disorder.25
The participant has a clinical diagnosis of ASD and ADHD, and is a
forensic in-patient. Finally, we identiﬁed a deletion at 19q13.32
comprising 56 genes. This deletion partially overlaps with a case
reported previously but does not include any of the proposed
candidate genes.26 The participant has a clinical diagnosis of depres-
sion and bipolar affective disorder.
DISCUSSION
Approximately 11% new diagnoses could be made by testing adults
with ID accessing psychiatry services in the UK. Recently there have
been calls for increased clinical use of CMA in patients with
schizophrenia. The yield of likely pathogenic CNVs in adults
with schizophrenia is reported to be in the range of 2.5–5%.27,28
Our higher diagnostic yield argues that clinicians should also consider
adopting routine CMA in ID psychiatry. Interestingly the most
frequently observed CNV in this study was the 16p11.2 duplication
(4 individuals, 2%). This CNV has been widely reported in other
studies, with a frequency of ~ 0.2% in DD/ID,29 ~ 1% in ASD5 and
~ 0.3% in schizophrenia.28 Accepting the small sample size this may
suggest a particular enrichment of this recurrent CNV in the adult
Figure 1 Overview of likely pathogenic CNVs identiﬁed in a sample of 202 adults with idiopathic intellectual disabilities and comorbid psychiatric disorders.
Number of participants, approximate CNV size in megabases or kilobases (Mb or Kb), breakpoints (BP) and exon number are displayed in parenthesis as
appropriate.
CMA in ID and comorbid psychiatric disorders
K Wolfe et al
68
European Journal of Human Genetics
Ta
bl
e
1
Li
ke
ly
pa
th
og
en
ic
C
N
Vs
an
d
ps
yc
hi
at
ric
ph
en
ot
yp
es
in
ad
ul
ts
w
ith
ID
re
fe
rr
ed
to
ps
yc
hi
at
ric
se
rv
ic
es
D
ec
ip
he
r
ID
Cy
to
ge
ne
tic
lo
ca
tio
n
G
ai
n/
lo
ss
Ch
ro
m
os
om
al
re
gi
on
G
en
de
r
Ag
e
Le
ve
l
of
ID
Ps
yc
hi
at
ric
hi
st
or
y
M
in
iP
AS
-A
D
D
B
PI
-S
Et
hn
ic
ity
3
2
7
1
3
8
2p
16
.3
Lo
ss
hg
19
ch
r2
:g
.(5
11
27
94
0_
51
19
61
88
)_
(5
17
45
53
2_
51
90
59
88
)d
el
Fe
m
al
e
2
1
M
od
er
at
e
P
D
P
S
Y,
U
N
S
—
—
+
W
hi
te
(B
rit
is
h)
3
2
7
1
3
6
2q
13
Lo
ss
hg
1
9
ch
r2
:g
.(
1
1
13
4
3
0
3
2
_1
1
1
3
9
4
4
6
4)
_(
11
3
1
0
1
4
3
2
_1
1
3
1
1
5
81
6
)d
el
M
al
e
1
9
M
ild
A
S
D
A
N
X,
P
SY
+
+
+
W
hi
te
(B
rit
is
h)
3
2
7
1
3
4
4p
16
.3
G
ai
n
hg
1
9
ch
r4
:g
.(
?_
1
1
6
6
4
3
)_
(2
5
9
32
6
5
_2
6
4
1
5
5
4
)d
up
M
al
e
3
3
M
ild
A
S
D
,
A
LC
,
FO
R
N
A
N
A
W
hi
te
(B
rit
is
h
3
2
7
1
3
1
6p
25
.3
-2
4
.3
a
G
ai
n
hg
1
9
ch
r6
:g
.(
?_
1
9
5
4
3
8
)_
(7
3
9
16
0
5
_7
4
1
4
8
6
6
)d
up
M
al
e
4
9
M
ild
A
N
X,
D
E
P
H
YP
,
P
SY
,
A
S
D
—
+
+
W
hi
te
(B
rit
is
h)
3
2
7
1
2
0
12
p1
3
.1
G
ai
n
hg
1
9
ch
r1
2
:g
.(
1
37
4
9
9
7
1
_1
3
7
5
4
5
5
7
)_
(1
37
6
2
8
1
8
_1
3
8
0
9
9
1
3
)d
up
Fe
m
al
e
6
8
M
od
er
at
e
C
B
N
on
e
m
et
+
+
—
W
hi
te
(B
rit
is
h)
3
2
7
1
2
6
12
q2
1
.2
-2
1
.3
1
Lo
ss
hg
1
9
ch
r1
2
:g
.(
7
94
8
0
4
9
6
_7
9
5
3
4
6
4
8
)_
(8
45
3
5
8
2
4
_8
4
5
9
7
2
4
8
)d
el
M
al
e
3
1
M
ild
S
C
Z,
A
LC
,
FO
R
H
YP
,
P
SY
—
—
—
B
la
ck
(A
fr
ic
an
)
3
2
7
1
2
5
13
q3
2
.3
-3
3
.3
G
ai
n
hg
1
9
ch
r1
3
:g
.(
1
00
4
4
8
3
2
8
_1
0
0
4
6
5
7
60
)_
(1
0
9
5
7
8
0
7
2
_1
0
9
6
1
71
1
2
)
du
p
M
al
e
2
1
M
ild
A
S
D
,
A
D
H
D
,
FO
R
N
on
e
m
et
—
—
—
W
hi
te
(B
rit
is
h)
3
2
7
1
2
8
15
q1
1
.2
Lo
ss
hg
1
9
ch
r1
5
:g
.(
2
27
2
8
6
9
6
_2
2
7
5
9
7
1
6
)_
(2
30
7
1
8
1
4
_2
3
1
4
9
1
6
8
)d
el
Fe
m
al
e
4
2
M
od
er
at
e
B
P
D
E
P
,
A
N
X,
H
YP
,
O
C
D
,
PS
Y,
U
N
S
—
—
+
W
hi
te
(B
rit
is
h)
3
2
7
1
2
7
15
q1
1
.2
-1
3
.1
Lo
ss
hg
1
9
ch
r1
5
:g
.(
2
35
1
0
7
1
2
_2
3
6
4
3
1
0
0
)_
(2
85
1
9
1
4
2
_2
8
5
6
5
6
6
2
)d
el
Fe
m
al
e
3
3
S
ev
er
e
A
N
X
A
N
X
+
—
+
W
hi
te
(B
rit
is
h)
3
2
7
1
2
4
15
q1
1
.2
-1
3
.1
G
ai
n
hg
1
9
ch
r1
5
:g
.(
2
37
8
0
8
2
2
_2
3
8
1
0
4
8
4
)_
(2
85
1
9
1
4
2
_2
8
5
6
5
6
6
2
)d
up
M
al
e
2
2
M
ild
A
S
D
,
B
P
,
P
D
,
A
LC
,
FO
R
N
A
—
+
—
W
hi
te
(B
rit
is
h)
3
2
7
1
2
3
15
q1
2
-1
3
.1
Lo
ss
hg
1
9
ch
r1
5
:g
.(
2
64
4
5
2
5
6
_2
6
4
5
5
7
6
4
)_
(2
95
7
6
8
7
2
_2
9
5
8
2
4
3
6
)d
el
M
al
e
2
8
S
ev
er
e
A
S
D
,
A
D
H
D
O
C
D
,
A
S
D
+
+
+
W
hi
te
(O
th
er
)
3
2
7
1
3
7
15
q1
3
.2
-1
3
.3
Lo
ss
hg
1
9
ch
r1
5
:g
.(
3
03
5
7
6
7
6
_3
0
4
6
1
1
9
0
)_
(3
28
0
4
2
1
0
_3
2
9
0
6
8
0
6
)d
el
M
al
e
2
5
M
ild
A
S
D
b
N
on
e
m
et
—
—
—
W
hi
te
(B
rit
is
h)
3
2
7
1
2
2
16
p1
1
.2
G
ai
n
hg
1
9
ch
r1
6
:g
.(
2
93
8
7
6
0
4
_2
9
4
4
3
9
8
4
)_
(3
01
9
2
5
6
2
_3
0
3
5
1
3
8
0
)d
up
Fe
m
al
e
3
3
M
ild
A
FF
D
E
P
,
A
N
X,
P
S
Y
—
—
—
W
hi
te
(B
rit
is
h)
3
2
7
1
1
9
16
p1
1
.2
G
ai
n
hg
1
9
ch
r1
6
:g
.(
2
95
6
5
7
0
0
_2
9
7
4
6
3
2
4
)_
(3
00
9
3
4
6
8
_3
0
1
9
2
5
6
2
)d
up
Fe
m
al
e
2
7
M
ild
A
S
D
,
D
E
P
,
O
C
D
D
E
P
,
O
C
D
—
—
—
W
hi
te
(O
th
er
)
3
2
7
1
2
1
16
p1
1
.2
G
ai
n
hg
1
9
ch
r1
6
:g
.(
2
95
6
5
7
0
0
_2
9
7
4
6
3
2
4
)_
(3
00
9
3
4
6
8
_3
0
1
9
2
5
6
2
)d
up
Fe
m
al
e
6
2
M
ild
D
E
P
(p
sy
ch
ot
ic
)
P
S
Y
—
—
—
W
hi
te
(B
rit
is
h)
3
2
7
1
3
3
16
p1
1
.2
G
ai
n
hg
1
9
ch
r1
6
:g
.(
2
95
6
5
7
0
0
_2
9
7
4
6
3
2
4
)_
(3
01
9
2
5
6
2
_3
0
3
5
1
3
8
0
)d
up
M
al
e
2
1
M
ild
A
S
D
,
A
D
H
D
,
FO
R
N
on
e
m
et
—
+
—
W
hi
te
(B
rit
is
h)
3
2
7
1
3
5
16
p1
1
.2
Lo
ss
hg
1
9
ch
r1
6
:g
.(
2
95
6
5
7
0
0
_2
9
7
4
6
3
2
4
)_
(3
01
9
2
5
6
2
_3
0
3
5
1
3
8
0
)d
el
M
al
e
1
9
M
ild
N
on
e
re
co
rd
ed
D
E
P
,
A
N
X,
H
YP
,
O
C
D
,
PS
Y
—
—
+
W
hi
te
(B
rit
is
h)
3
2
7
1
3
0
16
p1
3
.1
1
G
ai
n
hg
1
9
ch
r1
6
:g
.(
1
48
8
0
5
7
5
_1
4
8
9
2
2
1
5
)_
(1
66
1
6
4
2
6
_1
6
6
2
5
0
7
4
)d
up
Fe
m
al
e
4
5
M
od
er
at
e
C
B
N
A
N
A
W
hi
te
(B
rit
is
h)
3
2
7
1
3
2
17
q1
1
.2
Lo
ss
hg
1
9
ch
r1
7
:g
.(
2
90
2
3
5
4
0
_2
9
0
6
8
1
4
4
)_
(3
02
8
1
8
5
6
_3
0
4
5
8
9
0
0
)d
el
M
al
e
5
7
S
ev
er
e
A
S
D
,
C
B
A
N
X,
H
YP
,
O
C
D
+
+
+
W
hi
te
(B
rit
is
h)
3
2
7
1
3
1
18
p1
1
.3
2
-1
1
.3
1
a
Lo
ss
hg
1
9
ch
r1
8
:g
.(
1
22
3
7
9
_1
4
1
4
9
1
)_
(6
9
6
4
2
01
_7
0
1
03
3
4
)d
el
M
al
e
4
9
M
ild
A
N
X,
D
E
P
H
YP
,
P
SY
,
A
S
D
—
+
+
W
hi
te
(B
rit
is
h)
3
2
7
1
2
9
19
q1
3
.3
2
Lo
ss
hg
1
9
ch
r1
9
:g
.(
4
56
8
4
6
2
4
_4
5
7
4
1
7
4
0
)_
(4
72
6
8
1
3
6
_4
7
3
0
9
1
4
0
)d
el
Fe
m
al
e
5
8
M
ild
B
P
D
E
P
,
P
SY
—
+
—
W
hi
te
(B
rit
is
h)
3
2
7
1
3
9
Xq
24
-2
5
G
ai
n
hg
1
9
ch
rX
:g
.(
11
8
8
5
5
8
8
8
_1
1
8
8
8
3
24
8
)_
(1
2
3
2
8
3
2
9
6_
12
3
3
49
0
9
6
)d
up
M
al
e
5
7
M
od
er
at
e
C
B
N
on
e
m
et
—
+
+
B
la
ck
(C
ar
ib
be
an
)
N
A
XX
YY
G
ai
n
Fu
ll
ch
ro
m
os
om
al
du
pl
ic
at
io
ns
M
al
e
5
9
M
ild
D
E
P
,
FO
R
N
on
e
m
et
—
+
—
W
hi
te
(B
rit
is
h)
C
hr
om
os
om
al
re
gi
on
co
or
di
na
te
s
in
hg
1
9
us
in
g
th
e
H
G
VS
st
an
da
rd
no
m
en
cl
at
ur
e;
Ag
e,
ag
e
at
da
te
of
re
cr
ui
tm
en
t;
Le
ve
l
of
ID
,
ta
ke
n
fr
om
m
ed
ic
al
re
co
rd
s
in
ac
co
rd
an
ce
w
ith
th
e
U
K
IC
D
-1
0
di
ag
no
st
ic
sy
st
em
:
5
0–
6
9
,
m
ild
;
3
5
–
49
,
m
od
er
at
e;
2
0
–
3
4;
se
ve
re
.
M
in
i
PA
S-
A
D
D
,
Ps
yc
hi
at
ric
As
se
ss
m
en
t
S
ch
ed
ul
es
fo
r
A
du
lts
w
ith
D
ev
el
op
m
en
ta
l
D
is
ab
ili
tie
s
th
re
sh
ol
ds
m
et
(in
la
st
2
ye
ar
s)
;
B
PI
-S
,
th
e
B
eh
av
io
ur
Pr
ob
le
m
s
In
ve
nt
or
y-
Sh
or
t
Fo
rm
(s
el
f-
in
ju
rio
us
be
ha
vi
ou
r,
ag
gr
es
si
ve
/d
es
tr
uc
tiv
e,
st
er
eo
ty
pe
d)
ite
m
s
sc
or
ed
as
+
w
he
n
be
ha
vi
ou
r
oc
cu
rs
at
le
as
t
w
ee
kl
y;
P
D
,
pe
rs
on
al
ity
di
so
rd
er
;
P
SY
,
ps
yc
ho
si
s;
U
N
S,
un
sp
ec
iﬁ
ed
di
so
rd
er
;
AS
D
,
au
tis
tic
sp
ec
tr
um
di
so
rd
er
;
A
N
X,
an
xi
et
y
di
so
rd
er
;
AL
C
al
co
ho
l
ab
us
e;
FO
R
on
fo
re
ns
ic
in
-p
at
ie
nt
se
ct
io
n;
N
A
,
no
t
av
ai
la
bl
e;
D
E
P,
de
pr
es
si
on
;
H
YP
,
hy
po
m
an
ia
/m
an
ia
;
C
B
,
ch
al
le
ng
in
g
be
ha
vi
ou
r;
S
CZ
,
sc
hi
zo
ph
re
ni
a;
A
D
H
D
,
at
te
nt
io
n-
de
ﬁ
ci
t
hy
pe
ra
ct
iv
ity
di
so
rd
er
;
B
P,
bi
po
la
r
di
so
rd
er
;
O
C
D
,
ob
se
ss
iv
e
co
m
pu
ls
iv
e
di
so
rd
er
;
A
FF
,
sc
hi
zo
af
fe
ct
iv
e
di
so
rd
er
.
a C
N
Vs
in
th
e
sa
m
e
pa
rt
ic
ip
an
t.
b A
SD
tr
ai
ts
on
ly
.
CMA in ID and comorbid psychiatric disorders
K Wolfe et al
69
European Journal of Human Genetics
population of ID and comorbid psychiatric disorder. The yield of
VOUS CNVs in the study also appears to be high at 62%. This is of
considerable interest for future research, although it is difﬁcult to
determine whether VOUS are enriched in this cohort due to lack of
comparable data sets.
A broad range of psychiatric diagnoses/symptoms were observed
across the cohort. The pattern of comorbidities, either deﬁned by
ICD-10 diagnoses or Mini PAS-ADD thresholds, was complex.
Inclusion of Mini PAS-ADD thresholds indicated a burden of
psychopathology not captured by ICD-10 diagnoses. It is of interest
that 41% of participants with likely pathogenic CNVs met the Mini
PAS-ADD threshold for psychosis, whereas based upon ICD-10
criteria this was only 14%, see Table 2. Overall psychiatric features
did not differentiate the likely pathogenic and likely benign CNV
groups. However there was an excess of participants on a forensic
section in the likely pathogenic CNV group in comparison with the
benign (including VOUS) CNV group. No link can be made
between speciﬁc CNVs and offending behaviour, as causality
cannot be inferred. The population of people with ID and
convictions is particularly marginalised and it may be that increased
barriers to genetic testing have resulted in a higher prevalence
of undiagnosed CNVs. This ﬁnding warrants further investigation
in much larger samples. Assessment of adults with ID and
formulation of the psychiatric presentation can be challenging.
The majority of likely pathogenic CNVs were found at recurrent
CNV loci where, at least some, information on the associated
phenotype is available. Such information may aid understanding
of the patient’s clinical presentation for both clinicians and
family members. Furthermore knowledge of associated pheno-
types may guide psychiatric evaluation. For example the identiﬁca-
tion of a 16p11.2 duplication would be an indicator to screen
for the presence of ASD, psychosis or affective disorders.15
Importantly some of the CNV syndromes are also associated with
non-psychiatric comorbidities that require speciﬁc medical man-
agement or monitoring. For example we identiﬁed an individual
with undiagnosed Angelman’s syndrome type 2 and an individual
with an NF1 deletion. Comprehensive medical guidelines are
available for Angelman’s syndrome and NF1 deletions.30 The
characterisation of very rare CNVs is an ongoing process and
clinical guidelines are being developed as new syndromes continue
to emerge. However, some diagnoses will have minimal impact on
patient management.
There is evidence for the beneﬁt to mothers in receiving a diagnosis
for a child with DD/ID.31 However, little is known about the impact
of disclosure of a genetic diagnosis to adults with ID or their
families/carers. Challenges are faced with ascertaining capacity to
consent to genetic testing, feedback of diagnoses and possible
incidental ﬁndings. We received no negative feedback from psychia-
trists in this study about the diagnostic process. All participants with
likely pathogenic CNVs were sent information about a rare chromo-
somal support group called Unique; this group is only accessible to
individuals with a diagnosis.14 Genetic diagnosis of the affected
individual provides the opportunity for cascade testing of at risk
relatives and the provision of recurrence risk information. The
inheritance of a likely pathogenic CNV in a child with associated
difﬁculties may be important in supporting an application for a
statement of special educational needs.
This study has several speciﬁc limitations. The sample size
was modest. The recruitment strategy focused on individuals
with a more severe psychiatric phenotype, that is, those presenting
to psychiatric services. We may have under sampled those with
the most severe phenotypes because of difﬁculties recruiting this
population group to research studies. However, our sample is
likely representative of individuals accessing specialist services
Table 2 Psychiatric phenotype (ICD-10 diagnoses, Mini PAS-ADD thresholds and section history) for likely pathogenic and benign CNVs
Total in sample (%)
n=202
Likely pathogenic CNV group (%)
n=22
Likely benign CNV group (%)
n=180
ICD-10 diagnosis
Psychosis 49 (25%) 3 (14%) 46 (26%)
Bipolar disorder 23 (11%) 3 (14%) 20 (11%)
Depressive episode 62 (31%) 4 (18%) 58 (32%)
Other anxiety disorders 45 (23%) 2 (9%) 43 (24%)
Hyperkinetic disorder 21 (10%) 3 (14%) 18 (10%)
Pervasive developmental disorder 68 (34%) 8 (36%) 60 (33%)
Mini PAS-ADD thresholds
Psychosis 72 (36%) 9 (41%) 63 (35%)
Hypomania/mania 33 (16%) 5 (23%) 28 (16%)
Depressive disorder 76 (38%) 5 (23%) 71 (39%)
Anxiety disorder 80 (40%) 6 (27%) 74 (41%)
Obsessive compulsive 55 (27%) 5 (23%) 50 (28%)
Mental Health Act Section History
Previous history of involuntary admission 45 (22%) 7 (32%) 38 (21%)
Forensic section 21 (10%) 6 (27%) 15 (8%)
ICD-10 diagnoses – the psychosis group was amalgamated to comprise: F20 schizophrenia, F25 schizoaffective disorder and F29 unspeciﬁed nonorganic psychosis. Other ICD-10 diagnoses reported
independently are: F31 bipolar disorder, F32 depressive episode, F41 other anxiety disorders, F90 hyperkinetic disorder, F84 pervasive developmental disorder. Mini PAS-ADD thresholds – scores
were calculated using standard guidelines, Mental Health Act (MHA) section – previous history of involuntary admission included previous and current MHA sections and forensic sections, forensic
section – all individuals were on a forensic section at the time of recruitment no history of being on a forensic section was identiﬁed in any of the other participants. Note: several individuals had
comorbid diagnoses and are included in more than one category.
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for ID and comorbid mental illness. Estimates of the penetrance
of particular phenotypes would require epidemiological based
studies. Another major limitation is the lack of inheritance status,
which is often used to inform interpretation of rare variants.
Technological limitations of the aCGH platform include inability
to detect balanced translocations, single-gene disorders and low-
level mosaicism. As the array platform has not been utilised in
research studies of control populations comparisons with other
studies is prone to technical confounds. Exome and whole-genome
sequencing, which is gradually coming into clinical practice, is
likely to increase the yield of genetic diagnoses for those with ID
and comorbid psychiatric disorders.
CONCLUSIONS
We have demonstrated that CNV screening using clinically available
CMA offers over one in ten new aetiological diagnoses for adults with
idiopathic ID presenting to psychiatric services in the UK. It may be
appropriate for ID psychiatrists to offer CMA more routinely in
assessment of people with ID and comorbid mental health problems,
particularly in forensic settings. Liaison between clinicians and genetic
services will be important for the interpretation of new genomic
investigations in clinical practice.32
Clinical and research data on emerging CNV syndromes are
strongly biased towards paediatric populations. However, the
full extent of the phenotype associated with a particular CNV
may only be realised in adulthood as psychiatric disorders
emerge. We found the 16p11.2 duplication to be particularly
frequent in this understudied adult population. We also add
psychiatric phenotypic information to very rarely observed and
novel likely pathogenic CNVs. CMA testing in adults could
potentially inform the clinical management of children with new
emerging likely pathogenic CNVs.
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